9 hrs ago
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial...
INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson's disease.
Boston Scientific's "Hold" Rating Reaffirmed at Wedbush
's stock had its "hold" rating reiterated by Wedbush in a research note issued on Thursday, AnalystRatingsNetwork reports.
Boston Scientific Now Covered by Analysts at Wedbush
The firm set a "neutral" rating on the stock. Several other analysts have also recently commented on the stock.
Boston Scientific Rating Reiterated by Piper Jaffray
's stock had its "neutral" rating reaffirmed by investment analysts at Piper Jaffray in a note issued to investors on Tuesday, Stock Ratings Network.com reports.
Boston Scientific Receives CE Mark Approval For GUIDEa DBS System
GUIDE DBS provides clinicians with 3D visualization information that simulates stimulation output, which may reduce programming time and enable more precise targeting of therapy.
Boston Scientific showcases one of the largest rooftop solar power...
Boston Scientific showcases one of the largest rooftop solar power installations in Massachusetts -- 3,900-panel project at the company's international distribution center in Quincy May 24, 2013 Boston Scientific Corporation celebrates Earth Week by inaugurating a 3,900-panel rooftop solar installation atop the company's international distribution ... (more)
Applied Clinical Trials
Boston Scientific Reports Lotus? Valve System Met Primary Performance Endpoint in Reprise II Trial
The Lotus Valve System is the first transcatheter aortic valve replacement device of its kind with an Adaptive Seal that is designed to minimize aortic regurgitation , a proven predictor of mortality, and is both fully repositionable and retrievable prior to release.